Bianca D. Santomasso, MD, PhD, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma with CAR T-cell therapy.
Bianca D. Santomasso, MD, PhD, assistant attending neurologist at Memorial Sloan Kettering Cancer Center, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) with chimeric antigen receptor (CAR) T-cell therapy.
The potential for relapse and the toxicities themselves both pose unique challenges with CAR T-cell therapy, Santomasso says. Some CAR T cells are administered in patients because of the risk of toxicity, so minimizing the risk of relapse and toxicities would be a great next step in the treatment paradigm. Additionally, Santomasso says it would be great if these treatments could even be moved to the outpatient setting. This has already been tested with 1 CAR T-cell therapy in clinical trials.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More